ClinicalTrials.gg
RecruitingNCT07391982DESTINATION 2Updated Nov 6, 2026

Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions

An interventional study of uniform dose radiotherapy and De-escalated dose radiotherapy in Prostate Cancer (Adenocarcinoma), sponsored by The Netherlands Cancer Institute. Recruiting at 1 site in Netherlands. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by The Netherlands Cancer Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 6, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute — 6 open to participants now, 7 under way, none of them phase 3. Prostatic Neoplasms · The Netherlands Cancer Institute.

Planned enrollment
7th of 13
54 · median 54
Started
2025
the only one that year
No phase
8 of 16
5 open now
Registered
16th of 16
by date

Among the 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 8 with no phase, and was the 16th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute, or all of them as a file.
02

Study summary

The goal of this clinical trial is to find out whether lowering the radiation dose to parts of the prostate without visible tumor on MRI can reduce side effects while still effectively treating prostate cancer in men with low or intermediate-risk prostate cancer.

The main questions it aims to answer are:

  • Does reducing the radiation dose to healthy prostate tissue lower the risk of bowel and urinary side effects?
  • Can we maintain good cancer control by keeping a high dose for MRI-visible tumor areas?

Researchers will compare two treatment approaches:

  • One group receives a uniform high dose to the entire prostate.
  • The other group receives a lower dose to healthy prostate tissue and a high dose only to visible tumor areas.

Participants will:

  • Receive two sessions of MRI-guided radiotherapy using an MR-Linac.
  • Complete questionnaires about urinary, bowel, and sexual health before and after treatment.
  • Have follow-up visits to monitor side effects and PSA levels for up to 2 years.
03

Conditions studied

  • Prostate Cancer (Adenocarcinoma)

Keywords

  • De-escalation
  • Radiotherapy
  • MR-Linac
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men aged ≥18 years
  2. Histological confirmation of prostate adenocarcinoma requiring radical radiotherapy
  3. Gleason score 3+3, 3+4 or 4+3 (ISUP Grade groups (GG) 1, 2 or 3)
  4. MRI-visible tumour(s) of PIRADS v2 grade 3 or higher and able to be delineated on T2 and diffusion-weighted imaging +/- dynamic contrast-enhanced imaging. Tumour nodule visible on MRI should be considered able to be boosted by treating clinician and \<2.5cm in maximal dimension. MRI must be performed within 3 months of trial entry
  5. The MRI-defined lesion must be confirmed as malignant on (any Gleason grade is sufficient as long as Gleason score is reported).
  6. MRI stages mT1 and T2 or mT3a with ≤ 1mm tumour outside gland AND otherwise favourable intermediate risk characteristics (Gleason 3+3, 3+4)(as staged by AJCC TNM 2018)
  7. PSA \<20 ng/ml prior to starting androgen deprivation therapy (ADT).
  8. 0-2
  9. Ability of the participant to understand and the willingness to sign a written (IC) form.
  10. Ability/willingness to comply with the patient reported outcome questionnaires schedule throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. to MRI (e.g. pacemaker, potentially mobile metal implant, claustrophobia)
  2. IPSS Score > 19
  3. High grade disease (GG3) occult to MRI-defined lesion. As a guide, any pathology for which you would consider surveillance is allowed outside of the MRI-defined area.
  4. Prostate volume >90cc
  5. Comorbidities which predispose to significant toxicity (e.g. inflammatory bowel disease) or preclude long term follow up
  6. Hip replacement, or other pelvic metalwork which causes artefact on diffusion-weighted imaging
  7. Previous pelvic radiotherapy
  8. Patients needing >6 months of ADT due to disease parameters.
  9. Previous invasive within the last 2 years excluding basal or squamous cell carcinomas of the skin, low risk non-muscle invasive bladder cancer (assuming cystoscopic follow up now negative) or small renal masses on surveillance.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Other
    Uniform dose SBRT

    Radiation: uniform dose radiotherapy

  • Other
    De-escalated dose SBRT

    Radiation: De-escalated dose radiotherapy

Interventions

  • Radiationuniform dose radiotherapy

    27 Gy dose in 2 fractions to the whole prostate+/- seminal vesicles with a 0mm PTV margin using MR-linac

  • RadiationDe-escalated dose radiotherapy

    The benign prostate +/- SV CTV will receive 20 Gy in 2 fractions with a 0mm PTV margin using MR-linac. The intraprostatic tumor masses (on MRI) will receive 27 Gy in 2 fractions. A 4mm GTV to PTV margin will be added to the in-traprostatic MR visible tumour to form PTV 27Gy.

06

What researchers measure

Primary outcomes

  1. Acute GU toxicity

    Physician-reported acute Grade 2 or higher CTCAE GU toxicity observed within 13 weeks of starting radiotherapy

    Time frame: within 13 weeks of starting radiotherapy

Secondary outcomes

  1. Dosimetry

    Estimate the accumulated dose differences between treatment arms in terms of dose to prostate CTV, rectum, urethra and bladder

    Time frame: During Radiotherapy treatment of 8 days

  2. Late GI toxicity

    Physician reported late GI toxicity according to CTCAE v5.0

    Time frame: 1 and 2 years after radiotherapy treatment

  3. Biochemical relapse-free survival

    Assess biochemical relapse-free survival for 2 years

    Time frame: 2 years

  4. Severity of erectile dysfunction experienced by patient

    The IIEF-5 patient reported outcomes (PROs) assess the acute severity of erectile dysfunction

    Time frame: Before radiotherapy treatment, and at 6, 12 and 24 months after radiotherapy treatment

  5. Acute GI toxicity

    Physician reported acute GI toxicity according to CTCAE v5.0

    Time frame: At baseline, after the last fraction, and 2, 4 and 12 weeks after radiotherapy treatment

  6. Late GU toxicity

    Physician reported late GU toxicity according to CTCAE v5.0

    Time frame: 1 and 2 years after radiotherapy treatment

  7. Late sexual toxicity

    Physician reported late sexual toxicity according to CTCAE v5.0

    Time frame: 1 and 2 years after radiotherapy treatment

  8. Severity of urinary symptoms (GU) experienced by patient

    The patient reported outcomes (PROs) International Prostate Symptoms Score (IPSS) assess the severity of urinary symptoms what the patient experiences

    Time frame: Before radiotherapy treatment, after the last fraction, at 2, 4 and 12 weeks post-treatment, and at 6, 12 and 24 months after radiotherapy treatment

  9. Health-related quality of life experienced by patient

    The EPIC-26 patient reported outcomes (PROs) assess the health-related quality of life

    Time frame: Before start radiotherapy, week 4 and week 12, at 6, 12 and 24 months after radiotherapy treatment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — It is intended that data will be shared within the MOMENTUM collaboration, between centres delivering treatment in the same way as DESTINATION2. Pseudonymised data will be stored within MOMENTUM for at least 5 years. Storage will be cloud based and as the treating centre we will have free access to the data and control over who else can assess it.

Time frame: 5 years

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 15 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Feb 6, 2026
StartActual
Nov 17, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Dec 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Collaborators added: Radiotherapiegroep
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Sponsor Collaborators added: Radiotherapiegroep
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07391982
Collaborators
MRL Consortium, Elekta Limited, Radiotherapiegroep
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Nov 17, 2025
Primary completion
Feb 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Floris Pos, MD, PhD
Contact
f.pos@nki.nl
+31205129111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion